Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

January 2022

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions
EFFECTIVE 1 JANUARY 2022

- Aflibercept (Eylea) inj 40 mg per ml, 0.1 ml vial – amended restriction criteria
- Bisacodyl (Pharmacy Health) tab 5 mg – new listing and addition of PSS
- Bisacodyl (Lax-tabs) tab 5 mg – to be delisted 1 June 2022
- Bupivacaine hydrochloride with adrenaline inj 2.5 mg with adrenaline 1:200,000, 10 ml ampoule – new presentation listing
- Bupivacaine hydrochloride with fentanyl (Bupafen NRFit) inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe – delisted 1 January 2022
- Colchicine (Colgout) tab 500 mcg – price increase
- Corticorelin inj 100 mcg vial – chemical name change
- Docusate sodium with sennosides (Laxsol) tab 50 mg with sennosides 8 mg – price increase
- Doxazosin (Doxazosin Clinect) tab 2 mg and 4 mg – new listing
- Doxazosin (Apo-Doxazosin) tab 2 mg and 4 mg – to be delisted 1 September 2022
- Eplerenone (Inspra) tab 25 mg and 50 mg – price increase and addition of PSS
- Gelatine, succinylated (Gelofusine) inj 4%, 500 ml bag – price increase
- Glycine (B Braun) irrigation soln 1.5%, 3,000 ml bag – price increase
- Hydroxychloroquine (Plaquenil) tab 200 mg – price increase
- Lidocaine [lignocaine] hydrochloride with adrenaline inj 1% with adrenaline 1:1,000,000, 20 ml vial – new presentation listing
- Lisinopril (Ethics Lisinopril) tab 5 mg, 10 mg and 20 mg – price increase
- Losartan potassium with hydrochlorothiazide (Arrow-Losartan & Hydrochlorothiazide) tab 50 mg with hydrochlorothiazide 12.5 mg – price increase
- Megestrol acetate (Apo-Megestrol) tab 160 mg – to be delisted 1 May 2022
- Octreotide (Max Health) inj 50 mcg per ml, 100 mcg per ml, 500 mcg per ml, 1 ml ampoule – new listing and addition of PSS
- Octreotide (DBL Octreotide) inj 50 mcg per ml, 100 mcg per ml, 500 mcg per ml, 1 ml ampoule – to be delisted 1 June 2022
- Oxybutynin (Alchemy Oxybutynin) tab 5 mg – new listing
- Oxycodone hydrochloride (Oxycodone Sandoz) tab controlled-release 5 mg, 10 mg, 20 mg, 40 mg and 80 mg – price increase and addition of PSS

Summary of decisions – effective 1 January 2022 (continued)

- Pancreatic enzyme cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) (Creon 10000) and cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U) (Creon 25000) – addition of PSS
- Perindopril (Coversyl) tab 2 mg and 4 mg – new listing and addition of PSS
- Phenoxymethylpenicillin [Penicillin V] (Cilicaine VK) cap 250 mg (Pharmacode 2602865) – new Pharmacode listing
- Phenoxymethylpenicillin [Penicillin V] (Cilicaine VK) cap 250 mg (Pharmacode 2048841) – Pharmacode to be delisted 1 July 2022
- Pneumococcal (PCV13) conjugate vaccine (Prevenar 13) Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe, 1 and 10 inj pack – amended restriction criteria
- Ranibizumab inj 10 mg per ml, 0.23 ml vial and 0.3 ml vial – amended restriction criteria
- Sodium chloride (B Braun) irrigation soln 0.9%, 3,000 ml bag – price increase
- Sodium chloride (BD PosiFlush) inj 0.9%, 3 ml, 5 ml and 10 ml syringe, non-sterile pack – price increase
- Teicoplanin (Targocid) inj 400 mg vial – new listing and addition of PSS
- Teicoplanin (Teicoplanin Mylan) inj 400 mg vial – to be delisted 1 June 2022
- Water (B Braun) irrigation soln, 3,000 ml bag – price increase

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 January 2022

ALIMENTARY TRACT AND METABOLISM

12	PANCREATIC ENZYME (addition of PSS)			
	Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) – **5% DV Jun-22 to 2024**	34.93	100	**Creon 10000**
	Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U) – **5% DV Jun-22 to 2024**	94.38	100	**Creon 25000**
14	DOCUSATE SODIUM WITH SENNOSIDES (↑ price)			
	Tab 50 mg with sennosides 8 mg	4.20	200	Laxsol
15	BISACODYL (brand change and addition of PSS)			
	Tab 5 mg – **5% DV Jun-22 to 2024**	5.80	200	**Pharmacy Health**
	Note – Lax-Tabs tab 5 mg to be delisted 1 June 2022.			

BLOOD AND BLOOD FORMING ORGANS

40	SODIUM CHLORIDE (↑ price)			
	➔ Inj 0.9%, 3 ml syringe, non-sterile pack	168.00	480	BD PosiFlush
	➔ Inj 0.9%, 5 ml syringe, non-sterile pack	169.92	480	BD PosiFlush
	➔ Inj 0.9%, 10 ml syringe, non-sterile pack	177.60	480	BD PosiFlush

CARDIOVASCULAR SYSTEM

40	GELATINE, SUCCINYLATED (↑ price)			
	Inj 4%, 500 ml bag	129.00	10	Gelofusine
42	LISINOPRIL (↑ price)			
	Tab 5 mg	17.50	90	Ethics Lisinopril
	Tab 10 mg	17.50	90	Ethics Lisinopril
	Tab 20 mg	17.50	90	Ethics Lisinopril
42	PERINDOPRIL (new listing and addition of PSS)			
	Tab 2 mg – **5% DV Jan-22 to 2024**	1.58	30	**Coversyl**
	Tab 4 mg – **5% DV Jan-22 to 2024**	2.95	30	**Coversyl**
43	LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE (↑ price)			
	Tab 50 mg with hydrochlorothiazide 12.5 mg	15.25	30	Arrow-Losartan & Hydrochlorothiazide
43	DOXAZOSIN (brand change)			
	Tab 2 mg	17.35	500	Doxazosin Clinect
	Tab 4 mg	20.94	500	Doxazosin Clinect
	Note – Apo-Doxazosin tab 2 mg and 4 mg to be delisted 1 September 2022.			

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 January 2022 (continued)				
48	EPLERENONE (↑ price and addition of PSS)			
	➔Tab 25 mg – **5% DV Jun-22 to 2024**	18.50	30	**Inspra**
	➔Tab 50 mg – **5% DV Jun-22 to 2024**	25.00	30	**Inspra**
GENITO-URINARY SYSTEM				
66	OXYBUTYNIN – Restricted: For continuation only (new listing)			
	➔Tab 5 mg	5.42	100	Alchemy Oxybutynin
HORMONE PREPARATIONS				
71	**CORTICORELIN** ~~CORTICOTRORELIN~~ (OVINE) (chemical name change)			
	Inj 100 mcg vial			
INFECTIONS				
81	PHENOXYMETHYLPENICILLIN [PENICILLIN V] (Pharmacode change)			
	Cap 250 mg – **5% DV Jan-22 to 2024**	3.84	50	**Cilicaine VK**
	Note – this listing is for Pharmacode 2602865. Pharmacode 2048841 to be delisted 1 July 2022.			
85	TEICOPLANIN (brand change and addition of PSS)			
	➔Inj 400 mg vial – **5% DV Jun-22 to 2024**	49.95	1	**Targocid**
	Note – Teicoplanin Mylan inj 400 mg vial to be delisted 1 June 2022.			
MUSCULOSKELETAL SYSTEM				
101	HYDROXYCHLOROQUINE (↑ price)			
	➔Tab 200 mg	8.78	100	Plaquenil
106	COLCHICINE (↑ price)			
	Tab 500 mcg	10.06	100	Colgout
NERVOUS SYSTEM				
111	BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE (new presentation listing)			
	Inj 2.5 mg per ml with adrenaline 1:200,000, 10 ml ampoule			
113	BUPIVACAINE HYDROCHLORIDE WITH FENTANYL (delisting)			
	Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe	36.00	5	Bupafen NRFit
	Note – Bupafen NRFit inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe delisted 1 January 2022.			
113	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE (new presentation listing)			
	Inj 1% with adrenaline 1:100,000, 20 ml vial			
116	OXYCODONE HYDROCHLORIDE (↑ price and addition of PSS)			
	Tab controlled-release 5 mg – **5% DV Jun-22 to 2024**	2.69	20	**Oxycodone Sandoz**
	Tab controlled-release 10 mg – **5% DV Jun-22 to 2024**	2.69	20	**Oxycodone Sandoz**
	Tab controlled-release 20 mg – **5% DV Jun-22 to 2024**	3.49	20	**Oxycodone Sandoz**
	Tab controlled-release 40 mg – **5% DV Jun-22 to 2024**	5.49	20	**Oxycodone Sandoz**
	Tab controlled-release 80 mg – **5% DV Jun-22 to 2024**	12.99	20	**Oxycodone Sandoz**

Changes to Section H Part II – effective 1 January 2022 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

152 MEGESTROL ACETATE – Restricted: For continuation only (delisting)
➔ Tab 160 mg ..... 63.53 30 Apo-Megestrol
Note – Apo-Megestrol tab 160 mg to be delisted 1 May 2022.

153 OCTREOTIDE (brand change and addition of PSS)
Inj 50 mcg per ml, 1 ml ampoule
– **5% DV Jun-22 to 2024** ..... 27.58 5 **Max Health**
Inj 100 mcg per ml, 1 ml ampoule
– **5% DV Jun-22 to 2024** ..... 32.71 5 **Max Health**
Inj 500 mcg per ml, 1 ml ampoule
– **5% DV Jun-22 to 2024** ..... 113.10 5 **Max Health**
Note – DBL Octreotide inj 50 mcg per ml, 100 mcg per ml and 500 mcg per ml, 1 ml ampoule to be delisted 1 June 2022.

172 AFLIBERCEPT (amended restriction criteria – amended criteria shown only)
➔ Inj 40 mg per ml, 0.1 ml vial ..... 1,250.00 1 Eylea

Restricted
Initiation - Wet Age Related Macular Degeneration
Ophthalmologist **or nurse practitioner**
Re-assessment required after 3 months
Either:
1. All of the following:
   1.1. Any of the following:
      1.1.1. Wet age-related macular degeneration (wet AMD); or
      1.1.2. Polypoidal choroidal vasculopathy; or
      1.1.3. Choroidal neovascular membrane from causes other than wet AMD; and
   1.2. Either:
      1.2.1. The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
      1.2.2. There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
   1.3. There is no structural damage to the central fovea of the treated eye; and
   1.4. Patient has not previously been treated with ranibizumab for longer than 3 months; or
2. Either:
   2.1. Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
   2.2. Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Continuation - Wet Age Related Macular Degeneration
Ophthalmologist **or nurse practitioner**
Re-assessment required after 12 months
All of the following:
1. Documented benefit must be demonstrated to continue; and
2. Patient's vision is 6/36 or better on the Snellen visual acuity score; and
3. There is no structural damage to the central fovea of the treated eye.

continued...

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 January 2022 (continued)

continued...

Initiation - Diabetic Macular Oedema (DMO)
Ophthalmologist **or nurse practitioner**
Re-assessment required after 4 months
All of the following:
1. Patient has centre involving diabetic macular oedema (DMO); and
2. Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
3. Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
4. Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
5. There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Continuation - Diabetic Macular Oedema (DMO)
Ophthalmologist **or nurse practitioner**
Re-assessment required after 12 months
All of the following:
1. There is stability or two lines of Snellen visual acuity gain; and
2. There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
3. Patient's vision is 6/36 or better on the Snellen visual acuity score; and
4. There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
5. After each consecutive 12 months treatment with aflibercept, patient has retrialled with at least one injection of bevacizumab and had no response.

184 RANIBIZUMAB (amended restriction criteria)
➔ Inj 10 mg per ml, 0.23 ml vial
➔ Inj 10 mg per ml, 0.3 ml vial

Restricted
Initiation - Wet Age Related Macular Degeneration
Ophthalmologist **or nurse practitioner**
Re-assessment required after 3 months
Either:
1. All of the following:
   1.1. Any of the following:
      1.1.1. Wet age-related macular degeneration (wet AMD); or
      1.1.2. Polypoidal choroidal vasculopathy; or
      1.1.3. Choroidal neovascular membrane from causes other than wet AMD; and
   1.2. Either:
      1.2.1. The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
      1.2.2. There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
   1.3. There is no structural damage to the central fovea of the treated eye; and
   1.4. Patient has not previously been treated with aflibercept for longer than 3 months; or
2. Patient has current approval to use aflibercept for treatment of wAMD and was found to be intolerant to aflibercept within 3 months

Continuation - Wet Age Related Macular Degeneration
Ophthalmologist **or nurse practitioner**
Re-assessment required after 12 months
All of the following:
1. Documented benefit must be demonstrated to continue; and
2. Patient's vision is 6/36 or better on the Snellen visual acuity score; and
3. There is no structural damage to the central fovea of the treated eye.

Changes to Section H Part II – effective 1 January 2022 (continued)

VARIOUS

233 GLYCINE (↑ price)
Irrigation soln 1.5%, 3,000 ml bag ..... 33.20 4 B Braun

233 SODIUM CHLORIDE (↑ price)
Irrigation soln 0.9%, 3,000 ml bag ..... 28.80 4 B Braun

233 WATER (↑ price)
Irrigation soln, 3,000 ml bag ..... 30.95 4 B Braun

VACCINES

257 PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE (amended restriction criteria – amended criteria shown only)
➔ Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe ..... 0.00 1 Prevenar 13
10 Prevenar 13

Restricted
Initiation – High risk adults and children 5 years and over
Therapy limited to 4 doses
Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients 5 years and over with HIV, for patients pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, **intracranial shunts, cerebrospinal fluid leaks** or primary immunodeficiency.

Index

Pharmaceuticals and brands

New Zealand
Permit No. 478

Permit

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1172-3694 (Print)
ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand